NEW YORK, May 9 (GenomeWeb News) - Applera and Roche Diagnostics have settled their litigation over PCR technology and have included real-time PCR in their PCR licensing program, the companies said today.
The firms have settled their litigation and arbitration about contractual relationships that involved rights to and commercialization of PCR and real-time PCR under undisclosed financial terms.
The companies' licensing program will now include patents for real-time PCR "and other important PCR-related technology," according company statements. Applera's ABI group will be the sole licensor of Roche patents covering methods and reagents for PCR and real-time PCR for life science research and other applications.
Applera has also obtained a diagnostics license, with no right to sublicense, of Roche's nucleic acid technology patents.
In addition, Roche and Applera have granted each other licenses related to PCR technology for research and diagnostics. This includes the right for Roche to manufacture real-time PCR instruments for a third party under certain conditions.